A genetically modified rat model has been developed by deleting the Toll-like Receptor 4 (Tlr4) gene, creating the first instance of its kind in rats. This model has been successfully produced and characterized in vivo, making it a robust tool for studying immune responses and neurological functions. Its design enables researchers to explore Tlr4’s role in inflammation, neurological disorders, and various biological pathways. The rat’s larger size and closer physiological resemblance to humans, compared to mice, further enhance its utility, particularly in experimental contexts that require detailed investigation and precise data collection.
Description
What sets this technology apart is its pioneering approach and clear advantages over existing mouse models. The use of rats offers improved translational relevance, which is essential for advancing therapeutic research and drug development. Furthermore, its successful validation documented in published work, coupled with interest from major pharmaceutical companies, highlights its potential to drive future breakthroughs. The model remains unencumbered by prior patents, ensuring open opportunities for further exploration and commercialization in diverse areas of biomedical research.
Applications
- Drug discovery platform
- Preclinical efficacy testing
- Inflammatory disease research
- Neurological disorder modeling
Advantages
- Provides a novel Tlr4 knockout rat model that enhances the study of immune and nervous system functions.
- Offers a more physiologically relevant model compared to mice